Fievos L. Christofi

Fievos L. Christofi

Auto-generated profile, based on publicly available information

Fievos L. Christofi

The Ohio State University, Wexner Medical Center, Dept. of Anesthesiology, Columbus, OH, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2020 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
EMElvio Mazzotta
Elvio Mazzotta
EVEgina Criseida Villalobos-Hernandez
Egina Criseida Villalobos-Hernandez
JFJuan Fiorda-Diaz
Juan Fiorda-Diaz
AHAlan Harzman
Alan Harzman
FCFievos L. Christofi
Fievos L. Christofi
Postoperative ileus (POI) and postoperative gastrointestinal tract dysfunction (POGD) are well-known complications affecting patients undergoing intestinal surgery. GI symptoms include nausea, vomiting, pain, abdominal distention, bloating, and constipation. These iatrogenic disorders are associated with extended hospitalizations, increased morbidity, and health care costs into the billions and current therapeutic strategies are limited. This is a narrative review focused on recent concepts in the pathogenesis of POI and POGD, pipeline drugs or approaches to treatment. Mechanisms, cellular targets and pathways implicated in the pathogenesis include gut surgical manipulation and surgical trauma, neuroinflammation, reactive enteric glia, macrophages, mast cells, monocytes, neutrophils and ICC’s. The precise interactions between immune, inflammatory, neural and glial cells are not well understood. Reactive enteric glial cells are an emerging therapeutic target that is under intense investigation for enteric neuropathies, GI dysmotility and POI. Our review emphasizes current therapeutic strategies, starting with the implementation of colorectal enhanced recovery after surgery protocols to protect against POI and POGD. However, despite colorectal enhanced recovery after surgery, it remains a significant medical problem and burden on the healthcare system. Over 100 pipeline drugs or treatments are listed in Clin.Trials.gov. These include 5HT4R agonists (Prucalopride and TAK 954), vagus nerve stimulation of the ENS—macrophage nAChR cholinergic pathway, acupuncture, herbal medications, peripheral acting opioid antagonists (Alvimopen, Methlnaltexone, Naldemedine), anti-bloating/flatulence drugs (Simethiocone), a ghreline prokinetic agonist (Ulimovelin), drinking coffee, and nicotine chewing gum. A better understanding of the pathogenic mechanisms for short and long-term outcomes is necessary before we can develop better prophylactic and treatment strategies.

1 February 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
FOFernando Ochoa-Cortes
Fernando Ochoa-Cortes
FTFabio Turco
Fabio Turco
ALAndromeda Linan-Rico
Andromeda Linan-Rico
SSSuren Soghomonyan
Suren Soghomonyan
EWEmmett Whitaker
Emmett Whitaker
FCFievos L. Christofi
Fievos L. Christofi
The word “glia” is derived from the Greek word “γλoια,” glue of the enteric nervous system, and for many years, enteric glial cells (EGCs) were belie

19 December 2016 in Frontiers in Neuroscience
Verified
Journal Article
Open access
ALAndromeda Linan-Rico
Andromeda Linan-Rico
FOFernando Ochoa-Cortes
Fernando Ochoa-Cortes
ABArthur Beyder
Arthur Beyder
SSSuren Soghomonyan
Suren Soghomonyan
AZAlix Zuleta-Alarcon
Alix Zuleta-Alarcon
FCFievos L. Christofi
Fievos L. Christofi
Enterochromaffin cells (EC) synthesize 95% of the body 5-HT and release 5-HT in response to mechanical or chemical stimulation. EC cell 5-HT has physiological effects on gut motility, secretion and visceral sensation. Abnormal regulation of 5-HT occurs in gastrointestinal disorders and Inflammatory Bowel Diseases (IBD) where 5-HT may represent a key player in the pathogenesis of intestinal inflammation. The focus of this review is on mechanism(s) involved in EC cell ‘mechanosensation’ and critical gaps in our knowledge for future research. Much of our knowledge and concepts are from a human BON cell model of EC, although more recent work has included other cell lines, native EC cells from mouse and human and intact mucosa. EC cells are ‘mechanosensors’ that respond to physical forces generated during peristaltic activity by translating the mechanical stimulus (MS) into an intracellular biochemical response leading to 5-HT and ATP release. The emerging picture of mechanosensation includes Piezo 2 channels, caveolin-rich microdomains and tight regulation of 5-HT release by purines. The ‘purinergic hypothesis’ is that MS releases purines to act in an autocrine / paracrine manner to activate excitatory (P2Y1, P2Y4, P2Y6, A2A/A2B) or inhibitory (P2Y12, A1, A3) receptors to regulate 5-HT release. MS activates a P2Y1/Gαq/PLC/IP3-IP3R/SERCA Ca2+signaling pathway, an A2A/A2B–Gs/AC/cAMP-PKA signaling pathway, an ATP-gated P2X3 channel, and an inhibitory P2Y12 -Gi/o/AC-cAMP pathway. In human IBD, P2X3 is down regulated and A2B is up regulated in EC cells, but the pathophysiological consequences of abnormal mechanosensory or purinergic 5-HT signaling remain unknown. EC cell mechanosensation remains poorly understood.

1 August 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ALAndromeda Liñán-Rico
Andromeda Liñán-Rico
FTFabio Turco
Fabio Turco
FOFernando Ochoa-Cortes
Fernando Ochoa-Cortes
AHAlan Harzman
Alan Harzman
BNBradley J. Needleman
Bradley J. Needleman
FCFievos L. Christofi
Fievos L. Christofi
Background. Clinical observations or animal studies implicate enteric glial cells in motility disorders, irritable bowel syndrome, inflammatory bowel disease,

12 July 2023 in Neuroscience Letters
Verified
Journal Article
Open access
ALAndromeda Linan-Rico
Andromeda Linan-Rico
FOFernando Ochoa-Cortes
Fernando Ochoa-Cortes
RSReiner Schneider
Reiner Schneider
FCFievos L. Christofi
Fievos L. Christofi
Enteric glial cells are emerging as critical players in the regulation of intestinal motility, secretion, epithelial barrier function, and gut homeostasis in health and disease. Enteric glia react to intestinal inflammation by converting to a 'reactive glial phenotype' and enteric gliosis, contributing to neuroinflammation, enteric neuropathy, bowel motor dysfunction and dysmotility, diarrhea or constipation, 'leaky gut', and visceral pain. The focus of the minireview is on the impact of inflammation on enteric glia reactivity in response to diverse insults such as intestinal surgery, ischemia, infections (C. difficile infection, HIV-Tat-induced diarrhea, endotoxemia and paralytic ileus), GI diseases (inflammatory bowel diseases, diverticular disease, necrotizing enterocolitis, colorectal cancer) and functional GI disorders (postoperative ileus, chronic intestinal pseudo-obstruction, constipation, irritable bowel syndrome). Significant progress has been made in recent years on molecular pathogenic mechanisms of glial reactivity and enteric gliosis, resulting in enteric neuropathy, disruption of motility, diarrhea, visceral hypersensitivity and abdominal pain. There is a growing number of glial molecular targets with therapeutic implications that includes receptors for interleukin-1 (IL-1R), purines (P2X2R, A2BR), PPARα, lysophosphatidic acid (LPAR1), Toll-like receptor 4 (TLR4R), estrogen-β receptor (ERβ) adrenergic α-2 (α-2R) and endothelin B (ETBR), connexin-43 / Colony-stimulating factor 1 signaling (Cx43/CSF1) and the S100β/RAGE signaling pathway. These exciting new developments are the subject of the minireview. Some of the findings in pre-clinical models may be translatable to humans, raising the possibility of designing future clinical trials to test therapeutic application(s). Overall, research on enteric glia has resulted in significant advances in our understanding of GI pathophysiology.

1 October 2013 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
ALAndrómeda Liñán-Rico
Andrómeda Liñán-Rico
JWJacqueline E. Wunderlich
Jacqueline E. Wunderlich
IGIveta S. Grants
Iveta S. Grants
WFWendy L. Frankel
Wendy L. Frankel
JXJianjing Xue
Jianjing Xue
FCFievos L. Christofi
Fievos L. Christofi
Background. Alterations in 5-hydroxytryptamine (HT) signaling in inflamed gut may contribute to pathogenesis of inflammatory bowel diseases. Adenosine 5′-triph